Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026GuruFocus · 2 days ago
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026GuruFocus · Oct 3, 2026
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026GuruFocus · Oct 2, 2026
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming MechanismGuruFocus · Aug 28, 2026
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon CancerGuruFocus · Aug 26, 2026This Exchange Traded Note (ETN) provides investors with exposure to commodity markets by tracking futures contracts, rather than offering direct ownership of the physical goods themselves. The benchmark index that this ETN aims to replicate is composed of one or more futures agreements on the designated commodity. Its objective is to mirror the potential returns generated from two sources: firstly, a straightforward, unleveraged investment in those specific futures contracts, and secondly, the interest income that could be accrued from cash collateral placed in particular Treasury Bills.